Agree with this. Given the efficacy, it's the best way to proceed. The IC50 values also support this type of management.
I don't mean to lessen the fact that the drug causes AEs. The review documents at the time made that clear. However, this report says pancreatitis is running at ~30% versus 6% on study. Without seeing what the exact data are, I do suspect there is a bit of sensationalism in the analyst note.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.